Investigational Drug Details
| Drug ID: | D171 |
| Drug Name: | HM15211 |
| Synonyms: | -- |
| Type: | Biological drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | GLP-1 agonist; GIP agonist; Glucagon triple agonist |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Phase 2 on-going (NCT04505436) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0272 | NCT03744182 | Phase 1 | Completed | No Results Available | November 1, 2018 | September 29, 2021 | Details |
| L0301 | NCT04505436 | Phase 2 | Recruiting | No Results Available | July 29, 2020 | March 16, 2022 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title |
|---|